Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients

Valentina K. Todorova, Issam Makhoul, Ishwori Dhakal, Jeanne Wei, Annjanette Stone, Weleetka Carter, Aaron Owen, Vicki Klimberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy for breast cancer and to correlate the results with the risk for DOX-associated cardiotoxicity. We have identified 18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-α, ATP6V1G2-DDX39B, MSH5, MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C as potential candidates for association with DOX cardiotoxicity. These results, albeit preliminary and involving a small number of patients, are consistent with reports showing the presence of susceptibility loci within the HLA gene region for several inflammatory and autoimmune diseases, and with our previous findings indicating that the increased sensitivity to DOX cardiotoxicity was associated with dysregulation of genes implicated both in inflammation and autoimmune disorders.

Original languageEnglish (US)
Pages (from-to)1223-1229
Number of pages7
JournalOncology Research
Volume25
Issue number8
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Doxorubicin
Breast Neoplasms
HLA Antigens
Genes
Genetic Predisposition to Disease
Cardiotoxicity
Drug-Related Side Effects and Adverse Reactions
Psoriasis
Antineoplastic Agents
Autoimmune Diseases
Single Nucleotide Polymorphism
Hypersensitivity
Inflammation
Gene Expression
Drug Therapy
DNA
Neoplasms

Keywords

  • Breast cancer
  • Cardiotoxicity
  • Doxorubicin (DOX)
  • Genotyping

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients. / Todorova, Valentina K.; Makhoul, Issam; Dhakal, Ishwori; Wei, Jeanne; Stone, Annjanette; Carter, Weleetka; Owen, Aaron; Klimberg, Vicki.

In: Oncology Research, Vol. 25, No. 8, 2017, p. 1223-1229.

Research output: Contribution to journalArticle

Todorova, Valentina K. ; Makhoul, Issam ; Dhakal, Ishwori ; Wei, Jeanne ; Stone, Annjanette ; Carter, Weleetka ; Owen, Aaron ; Klimberg, Vicki. / Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients. In: Oncology Research. 2017 ; Vol. 25, No. 8. pp. 1223-1229.
@article{5c14744948ff427bb5f15abe64fcd4f7,
title = "Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients",
abstract = "Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy for breast cancer and to correlate the results with the risk for DOX-associated cardiotoxicity. We have identified 18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-α, ATP6V1G2-DDX39B, MSH5, MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C as potential candidates for association with DOX cardiotoxicity. These results, albeit preliminary and involving a small number of patients, are consistent with reports showing the presence of susceptibility loci within the HLA gene region for several inflammatory and autoimmune diseases, and with our previous findings indicating that the increased sensitivity to DOX cardiotoxicity was associated with dysregulation of genes implicated both in inflammation and autoimmune disorders.",
keywords = "Breast cancer, Cardiotoxicity, Doxorubicin (DOX), Genotyping",
author = "Todorova, {Valentina K.} and Issam Makhoul and Ishwori Dhakal and Jeanne Wei and Annjanette Stone and Weleetka Carter and Aaron Owen and Vicki Klimberg",
year = "2017",
doi = "10.3727/096504017X14876245096439",
language = "English (US)",
volume = "25",
pages = "1223--1229",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "8",

}

TY - JOUR

T1 - Polymorphic variations associated with doxorubicin-induced cardiotoxicity in breast cancer patients

AU - Todorova, Valentina K.

AU - Makhoul, Issam

AU - Dhakal, Ishwori

AU - Wei, Jeanne

AU - Stone, Annjanette

AU - Carter, Weleetka

AU - Owen, Aaron

AU - Klimberg, Vicki

PY - 2017

Y1 - 2017

N2 - Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy for breast cancer and to correlate the results with the risk for DOX-associated cardiotoxicity. We have identified 18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-α, ATP6V1G2-DDX39B, MSH5, MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C as potential candidates for association with DOX cardiotoxicity. These results, albeit preliminary and involving a small number of patients, are consistent with reports showing the presence of susceptibility loci within the HLA gene region for several inflammatory and autoimmune diseases, and with our previous findings indicating that the increased sensitivity to DOX cardiotoxicity was associated with dysregulation of genes implicated both in inflammation and autoimmune disorders.

AB - Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of various malignancies, and its use is associated with unpredictable cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient dependent, suggesting genetic predisposition. We have previously found that individual sensitivity to DOX cardiotoxicity was associated with differential expression of genes implicated in inflammatory response and immune trafficking, which was consistent with the increasing number of reports highlighting the important role of human leukocyte antigen (HLA) complex polymorphism in hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from patients treated with DOX-based chemotherapy for breast cancer and to correlate the results with the risk for DOX-associated cardiotoxicity. We have identified 18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-α, ATP6V1G2-DDX39B, MSH5, MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C as potential candidates for association with DOX cardiotoxicity. These results, albeit preliminary and involving a small number of patients, are consistent with reports showing the presence of susceptibility loci within the HLA gene region for several inflammatory and autoimmune diseases, and with our previous findings indicating that the increased sensitivity to DOX cardiotoxicity was associated with dysregulation of genes implicated both in inflammation and autoimmune disorders.

KW - Breast cancer

KW - Cardiotoxicity

KW - Doxorubicin (DOX)

KW - Genotyping

UR - http://www.scopus.com/inward/record.url?scp=85030115615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030115615&partnerID=8YFLogxK

U2 - 10.3727/096504017X14876245096439

DO - 10.3727/096504017X14876245096439

M3 - Article

VL - 25

SP - 1223

EP - 1229

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 8

ER -